Andreas Grauer, M.D.Chief Medical Officer
Dr. Andreas Grauer serves as Chief Medical Officer at Federation Bio, where he leads the clinical programs, harnessing the company’s first-in-class platform that combines the power of genetic engineering and synthetic consortium design to control systemic immune responses and broad metabolic functions.
Dr. Grauer is a highly tenured physician scientist and pharmaceutical executive with more than 20 years of industry experience. He previously served as Chief Medical Officer at Corcept Therapeutics, overseeing clinical development programs ranging from phase 1 to phase 3 in endocrinology and oncology, as well as metabolic and neurologic indications. Prior to Corcept Therapeutics, Dr. Grauer served as Vice President of Global Development at Amgen, leading clinical research efforts in bone, nephrology and inflammation. While at Amgen, he oversaw several large development programs spanning from early clinical research to FDA and international approvals and commercialization. Before his time at Amgen, he was Executive Medical Director for New Business and Technology Development and Global Medical Director for Bone at Procter & Gamble Pharmaceuticals.
Dr. Grauer is an Internist and Endocrinologist by training. He received his medical education at the University of Heidelberg in Germany and at the Royal Postgraduate Medical School at the Hammersmith Hospital in London, UK and his subsequent clinical training at the University of Heidelberg. He performed part of his postdoctoral research during a fellowship in Molecular and Cellular Endocrinology at the Baylor College of Medicine in Houston, TX, USA.
Dr. Grauer is an active member of numerous scientific societies around the world, has authored more than 100 manuscripts and book chapters in the field of endocrinology and metabolic diseases and has received multiple national and international research awards for his work. He has held a faculty appointment as an Associate Professor of Medicine at the University of Heidelberg, Germany since 1997.